Journal of Advanced Biomedical Sciences
JABS
Sat, Feb 22, 2025
[Archive]
Winter 2025
Back to the articles list |
Back to browse issues page
1- Department of Clinical Biochemistry, Fasa University of Medical Sciences, Fasa, Iran
2- Department of Biochemistry, School of Medicine, Emory University, Atlanta, Georgia, United States
3- Department of Clinical Biochemistry, Fasa University of Medical Sciences, Fasa, Iran ,miladpour90@yahoo.com
2- Department of Biochemistry, School of Medicine, Emory University, Atlanta, Georgia, United States
3- Department of Clinical Biochemistry, Fasa University of Medical Sciences, Fasa, Iran ,
Abstract: (47 Views)
Colorectal cancer (CRC) is the third most prevalent cancer worldwide and represents a significant public health concern. Given its complexity, further research is needed to elucidate the role of signaling pathways, particularly those involving long non-coding RNAs (LncRNAs). LncRNAs, which are non-coding RNAs exceeding 200 nucleotides in length, are transcribed by RNA polymerase II and play a crucial role in gene regulation. Altered expression of LncRNAs has been implicated in multiple diseases, including CRC, where they affect key cellular signaling pathways. In this regard, the upregulation of C6ORF176, CASC9er35e, ESCCAL-1, FBXL19-AS1, FGD5-AS1, FOXD3-AS1, LBX2-AntisenseRNA1, SLCO4A1-AS1, and HOTAIRM1, as well as the downregulation of RP11-462C24.1 and RPL34-AS1, has been linked to CRC progression. The urgency of CRC screening is underscored by its increasing incidence, with 14% of cases diagnosed in individuals under 50 years of age in 2021 and 40–45% of cases reported in adults in 2020 and in 2022, according to the Global Cancer Observatory (GLOBOCAN), there has been 1.14 million new diagnosed colon cancer and this number is projected to reach 1.99 million by 2050. Moreover, the annual global incidence surpasses 1.9 million new cases, particularly in Europe, Oceania, and North America. The development and spread of CRC may be mitigated by targeting key pathways such as cAMP/CREB, AKT/mTOR/EMT, Wnt/β-catenin, and nuclear factor (NF)-κB. In this review, we provide a comprehensive summary of novel LncRNAs associated with CRC, focusing on those that have been relatively underexplored. Our findings highlight their potential as both therapeutic targets and research tools, contributing to selective treatment strategies and further investigations aimed at expanding our understanding of CRC pathogenesis.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)